Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Quest Diagnostics IncorporatedNYSE: DGX
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of $574M rose 37.0% year over year, ahead of the -1.3% change in trailing-twelve-month free cash flow. Sequentially, it rose 73.9% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.
Context
- Free cash flow amounted to 12.3% of revenue in FY2025, up 3.1 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +37.0% holds above the trailing-twelve-month pace of -1.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 1.36B USD
- Year-over-year change
- +49.5%
- 4-year CAGR
- -7.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.36B | +49.5% |
| FY2024 | 2024-12-31 | 909M | +5.2% |
| FY2023 | 2023-12-31 | 864M | -34.2% |
| FY2022 | 2022-12-31 | 1.31B | -28.2% |
| FY2021 | 2021-12-31 | 1.83B | — |
Free Cash Flow vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's LTM Sep 2026 free cash flow of $1.38B is the largest of the 9 companies compared; the peer median is $259.7M.
- Its year-over-year change of -1.3% is the 2nd highest of 9, against a peer median of -10.6%.
- Free cash flow amounts to 11.6% of revenue for DGX, versus a peer median of 18.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.38B | -1.3% | +1.1% | 11.6% | |
| LTM Jun 2026 | $1.16B | -8.4% | -6.5% | 8.1% | |
| LTM Jun 2026 | $939M | -8.9% | +106.3% | 20.9% | |
| LTM Jul 2026 | $559.34M | +11.2% | -5.1% | 19.2% | |
| LTM Jun 2026 | $447.7M | -9.8% | -7.1% | 21.3% | |
| LTM Jun 2026 | $295.25M | -20.6% | -20.0% | 178.7% | |
| LTM Sep 2026 | $232.15M | -11.5% | -15.5% | 18.2% | |
| LTM Sep 2026 | $155.28M | -398.3% | — | 6.5% | |
| LTM Jun 2026 | $71.7M | -31.4% | — | 2.6% | |
| Peer median (excluding DGX) | $259.7M | -10.6% | -6.8% | 18.7% | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.08B | 1.02B | 908M | 921M | 1.05B |
| Depreciation & Amortization | 408M | 437M | 439M | 493M | 570M |
| Deferred Income Tax | (57M) | 1M | (49M) | 13M | 105M |
| Stock-Based Compensation | 79M | 77M | 77M | 88M | 88M |
| Change in Working Capital | 87M | 119M | (145M) | (201M) | 50M |
| Accounts Receivables | 81M | 246M | (15M) | (71M) | (106M) |
| Inventory | (20M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 35M | (149M) | (55M) | (67M) | 129M |
| Other Working Capital | (9M) | 22M | (75M) | (63M) | 27M |
| Other Non-Cash Items | (364M) | 69M | 42M | 20M | 27M |
| Operating Cash Flow | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B |
| Capital Expenditures | (403M) | (404M) | (408M) | (425M) | (527M) |
| Acquisitions (Net) | 424M | (144M) | (611M) | (2.16B) | (101M) |
| Purchases of Investments | (3M) | (5M) | 0 | 0 | 0 |
| Sales of Investments | 403M | 5M | 0 | 0 | 0 |
| Other Investing Activities | (400M) | 5M | (42M) | 41M | (3M) |
| Investing Cash Flow | 21M | (543M) | (1.06B) | (2.55B) | (631M) |
| Debt Repayment | (2M) | (2M) | 748M | 1.54B | (602M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 79M |
| Common Stock Repurchased | (2.2B) | (1.41B) | (275M) | (151M) | (450M) |
| Dividends Paid | (309M) | (305M) | (314M) | (331M) | (353M) |
| Other Financing Activities | (30M) | (17M) | 1M | 23M | (62M) |
| Financing Cash Flow | (2.54B) | (1.73B) | 160M | 1.08B | (1.39B) |
| Effect of Forex Changes | 0 | 0 | 0 | (7M) | 4M |
| Net Change in Cash | (286M) | (557M) | 371M | (137M) | (129M) |
| Free Cash Flow | 1.83B | 1.31B | 864M | 909M | 1.36B |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.